APG Asset Management Trims Bristol Myers Squibb Stake

Institutional investor reduces position in pharmaceutical company by 27.3%

Mar. 2, 2026 at 6:07pm

Got story updates? Submit your updates here. ›

APG Asset Management N.V., a major institutional investor, has reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 27.3% in the third quarter, according to a recent SEC filing. The fund now owns 1,552,455 shares of the biopharmaceutical company's stock, valued at $70,016,000.

Why it matters

This move by a large institutional investor like APG Asset Management provides insight into market sentiment and portfolio positioning around Bristol Myers Squibb. As a major pharmaceutical company, changes in ownership of BMY stock can signal broader trends in the industry and investor views on the company's performance and outlook.

The details

According to the SEC filing, APG Asset Management sold 581,891 shares of Bristol Myers Squibb during the third quarter, reducing its total position by 27.3%. The fund now owns approximately 0.08% of the company's outstanding shares. No specific reasons were given for the portfolio adjustment.

  • The filing covers the third quarter of the year.

The players

APG Asset Management N.V.

A major institutional investor and asset management firm based in the Netherlands.

Bristol Myers Squibb Company

A global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This reduction in ownership by a prominent institutional investor like APG Asset Management suggests potential shifts in market sentiment around Bristol Myers Squibb. However, without further details, it's difficult to determine the specific reasons behind the portfolio adjustment. Investors will likely continue to monitor ownership changes and analyst commentary around the pharmaceutical company's performance and outlook.